Roche’s subcutaneous Tecentriq meets Phase III NSCLC co-primary endpoints
In the trial, Tecentriq’s subcutaneous formulation safety profile was in line with that of IV Tecentriq.
Switzerland
Latest in
Switzerland
ADC Therapeutics begins dosing Phase Ib non-Hodgkin lymphoma study
The LOTIS-7 Phase Ib clinical trial will include multiple arms in dose escalation and dose expansion parts.
SGS Health implements Veeva’s application for streamlined trial design
Implementation of Vault EDC will enable SGS to translate complex protocols into user-friendly casebook designs.
Memo commences Phase I trial of antibody against BKV infection
The trial will analyse the safety, tolerability, and pharmacokinetics of MTX-005 in up to 56 subjects.
Kintara activates first European site of Phase II/III glioblastoma trial
The GBM AGILE trial is currently underway at 44 clinical centres in the US and Canada.
Emergex obtains approval to commence Phase I trial of Covid-19 vaccine
Subject dosing in the trial to assess safety and tolerability of the vaccine will begin in January next year.
AC Immune reports positive data from Alzheimer’s disease drug trial
Semorinemab was well-tolerated and had a tolerable safety profile in the Phase II trial.
Partner content
Novartis’ Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial
The safety profile of the drug in the Phase III BELINDA trial was in line with the already reported data.